文献速递骨软组织肉瘤与黑色素瘤

纳武利尤单抗联合伊匹木单抗治疗既往经治经典型卡波西肉瘤的II期单臂研究

Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).
PubMed 文献 · Ann Oncol · 2022-03-23

这项前瞻性II期单臂研究纳入18例既往系统治疗后进展的经典型卡波西肉瘤男性患者,给予纳武利尤单抗240 mg每2周联合伊匹木单抗1 mg/kg每6周。中位随访24.4个月,总缓解率87%,6个月和12个月无进展生存率分别为76.5%和58.8%,仅4例(22%)发生3-4级不良事件。

要点

  • 纳武利尤单抗联合伊匹木单抗在经治进展期经典型卡波西肉瘤中总缓解率达87%。
  • 中位无进展生存未达到,6个月和12个月无进展生存率分别为76.5%和58.8%。
  • 仅4例(22%)发生3-4级不良事件,2例患者避免了姑息性截肢。

核心结论

  • 这项前瞻性设计的II期研究显示纳武利尤单抗联合伊匹木单抗在进展期经典型卡波西肉瘤中具有 promising 活性,为该人群提供了新的治疗选择。

研究设计与样本

  • 前瞻性设计的II期单臂研究,纳入18例既往接受一线或以上系统治疗后进展、经PET/CT和/或体格检查可测量病灶的经典型卡波西肉瘤患者。
  • 治疗方案为纳武利尤单抗240 mg每2周联合伊匹木单抗1 mg/kg每6周,直至进展或毒性,最长24个月。
  • 主要终点为总缓解率,次要终点包括6个月无进展生存率和安全性。

主要发现

  • 18例男性患者入组,中位年龄76.5岁,入组时间为2018年4月至2020年12月。
  • 中位随访24.4个月,按RECIST v1.1评估的总缓解率为87%。
  • 13例可评估患者中,8例(62%)达到代谢完全缓解;6/13例治疗后达到病理完全缓解。
  • 2例患者避免了姑息性截肢;中位无进展生存未达到,6个月和12个月无进展生存率分别为76.5%和58.8%。
  • 仅4例(22%)发生3-4级不良事件;最常见的基因组改变为FOX1A基因双等位拷贝数缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Classical Kaposi sarcoma (cKS) is a rare human herpesvirus 8-associated sarcoma with limited treatment options. We evaluated the efficacy and safety of nivolumab in combination with ipilimumab in patients with previously treated progressive cKS. PATIENTS AND METHODS: cKS patients with progressive disease after one or more lines of systemic therapy and measurable disease by positron emission tomography/computed tomography and/or physical examination received nivolumab 240 mg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks until progression or toxicity for a maximum of 24 months. The primary endpoint was overall response rate; secondary endpoints included 6-month progression-free survival (PFS) rate and safety. Immune correlates were explored using immunohistochemistry, DNA sequencing (596/648 genes) and RNA sequencing (whole transcriptome hybrid capture) of tumor specimens and matched blood. RESULTS: Eighteen male patients (median age 76.5 years) were enrolled between April 2018 and December 2020. At a median follow up of 24.4 months, overall response rate by RECIST v1.1 was 87%. Metabolic complete response as assessed by positron emission tomography/computed tomography was observed in 8 of 13 (62%) assessable patients. Some 6/13 achieved pathological complete response after treatment. In two patients, palliative limb amputation was prevented. Median PFS was not reached. The 6- month and 12-month PFS rate was 76.5% and 58.8%, respectively. Only four patients (22%) experienced grade 3-4 adverse events. The most frequent genomic alteration was biallelic copy number loss of the FOX1A gene. The majority of tumors carried a low tumor mutational burden, were microsatellite stable, mismatch repair proficient, did not express programmed death-ligand 1, and displayed only low lymphocytic infiltrates, rendering them immunologically 'cold'. CONCLUSIONS: This prospectively designed phase II study of nivolumab and ipilimumab demonstrates promising activity of this combination in progressive cKS representing a new treatment option in this population.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Zer A, Icht O, Yosef L, et al. Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS). Ann Oncol. 2022. PMID: 35339649. doi:10.1016/j.annonc.2022.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。